摘要
目的观察不同铂类药物敏感性宫颈癌细胞中的microRNA(miR)-181a表达,提高宫颈癌的药物治疗效果。方法观察不同铂类药物敏感性人体标本与人宫颈鳞状癌细胞系中的miR-181a表达。通过聚合酶链式反应(PCR)与基因转染技术,在体内与体外试验中,对miR-181a表达与铂类药物的敏感性进行研究。结果在2株人宫颈鳞状癌细胞系与人体标本中对化学治疗(简称化疗)药物有耐受性的肿瘤细胞miR-181a高表达,在裸鼠移植瘤模型与经过转染的细胞系中miR-181a的过表达显著增强了化疗的耐药性,而转染了miR-181a抑制因子后,药物敏感性明显升高。结论 miR-181a在调控肿瘤细胞化疗耐药性中有重要的协调作用,研究为预测人宫颈鳞状细胞癌的化疗耐药性提供了一种基因标志物。
Objective To observe the expression of miR - 181a in the cervical cancer cells with different sensitivity to platinum drugs and to improve the effect of medication on cervical cancer. Methods The miR - 181a expression in human specimens and human cervical squamous carcinoma cell lines was observed. By using polymerase chain reaction（PCR） and the gene transfection technique, the study on miR - 181a expression and the platinum drugs sensitivity was conducted in the in vivo and in vitro experiments. Results In two strains of human cervical squamous carcinoma cell lines and human specimens, the tumor cell miR - 181a with tolerance to chemotherapy drugs was highly expressed. In the nude mice transplanted tumor model and transfected cell lines, the over expression of miR - 181a significantly enhanced the tolerance to chemotherapy, while after transfecting miR - 181a inhibitory factor, the drug sensitivity was increased significantly. Conclusion MiR - 181a has an important coordinating role in the regulation of tumor cell resistance to chemotherapy, this research provides a gene marker for predicting the chemotherapy drug resistance in human cervical squamous cell carcinoma.
出处
《中国药业》
CAS
2014年第15期17-20,共4页
China Pharmaceuticals
关键词
宫颈癌
顺铂
化学治疗
cervical cancer
cisplatin
chemotherapy
